How do we treat systemic lupus erythematosus in 2024?

In Poland, approximately 18.5 thousand people suffer from systemic lupus erythematosus (SLE) and over 4 thousand have a severe course of the disease, with involvement of internal organs. Due to the multisystem nature of the disease, care of a patient with SLE should be multidisciplinary. The aim of treatment is long-term survival of patients, protection against damage to vital organs, and optimization of quality of life. To achieve this, the goal disease should be in remission, and if this is not possible, it should have low activity. In the initial period of therapy, when internal organs are affected, it is often necessary to use intensive immunosuppression to control disease activity. Subsequently, to maintain the initial response to treatment and prevent disease relapse, less intensive immunosuppressive treatment is maintained to avoid therapy complications. Selection of appropriate medications should be individually tailored to each patient. This publication aims to present the therapeutic possibilities for SLE in 2024.